On 29 October 2025, Dr. Christoffer Hatlestad-Hall, postdoctoral researcher from the Oslo University Hospital and AI-Mind project partner, joined C2N Diagnostics at an online webinar organised by Cambridge Cognition to answer the following question about the advances in Alzheimer’s disease research: Can the integration of blood-based biomarker tests and digital cognitive assessments accelerate brain health research by improving detection, enhancing precise monitoring and improving therapeutic intervention? 

The 60-minute expert-led event (16:00–17:00 CET) explored how these potentially more accessible and cost-effective diagnostics can lead to more efficient trials, from improved recruitment to more compelling evidence for regulators.  

During the session, Dr. Hatlestad-Hall presented insights from the AI-MIND project, highlighting how artificial intelligence–driven tools can support earlier identification of individuals at risk of developing dementia. He discussed the project’s work on integrating EEG-based brain network analytics with cognitive assessments to create scalable, non-invasive solutions for clinical and research settings. 

Together with experts from C2N Diagnostics, the panel demonstrated how combining advanced blood-based biomarker testing with digital cognitive tools offers a powerful opportunity to transform the diagnostic pathway. The speakers outlined emerging evidence showing that multimodal approaches may increase the accuracy of early detection, improve patient stratification, and support more targeted intervention strategies. 

The webinar closed with an interactive Q&A session, in which participants from academia, clinical practice and industry raised questions about real-world implementation, data harmonisation, and the future regulatory landscape. The discussion underscored the shared commitment across the field to advance accessible, science-driven technologies that can meaningfully improve brain health research and patient outcomes. 

AI-Mind is pleased to have contributed to this event and to continue fostering dialogue with leading organisations working to accelerate innovation in Alzheimer’s disease diagnostics.